Tacrine
As of the edition of 20 October 2026, Tacrine is a small molecule: marketed, first approved in 1993 (US); acts on ACHE and BCHE; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1993
- Kind
- Small molecule
- Brand name
- Cognex
- First approved
- 9 September 1993 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Shionogi
- Registered trials
- 1, 1 stopped early
- Disease areas
- Chemically induced; Mental health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Tacrine.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 1 |